AbCellera Biologics Inc. (ABCL)
| Market Cap | 3.69B +169.4% |
| Revenue (ttm) | 66.17M +101.3% |
| Net Income | -164.66M |
| EPS | -0.55 |
| Shares Out | 324.05M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 12,375,083 |
| Open | 10.84 |
| Previous Close | 10.97 |
| Day's Range | 10.47 - 11.50 |
| 52-Week Range | 2.75 - 11.50 |
| Beta | 1.19 |
| Analysts | Strong Buy |
| Price Target | 17.13 (+50.53%) |
| Earnings Date | Aug 5, 2026 |
About ABCL
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lil... [Read more]
Financial Performance
In 2025, AbCellera Biologics's revenue was $75.13 million, an increase of 160.56% compared to the previous year's $28.83 million. Losses were -$146.41 million, -10.10% less than in 2024.
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for ABCL stock is "Strong Buy." The 12-month stock price target is $17.13, which is an increase of 50.53% from the latest price.
News
AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants.
AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants.
AbCellera Biologics Slides: Corporate presentation
AbCellera Biologics has posted slides in relation to its latest quarterly earnings report, which was published on August 10, 2026.
AbCellera Biologics Transcript: Study result
Phase II data for ABCL635 in moderate to severe VMS showed robust efficacy, with significant reductions in symptom frequency and severity, high rates of complete resolution, and favorable safety. The once-monthly injectable offers strong differentiation from current therapies and addresses a major unmet need.
AbCellera Biologics Press release: Study result
AbCellera Biologics issued a press release on August 10, 2026, disclosing material business information to investors.
AbCellera Biologics Slides: Study result
AbCellera Biologics has posted slides in relation to its latest quarterly earnings report, which was published on August 10, 2026.
This Biotech's Drug Could Treat Hot Flashes. The Stock Is Up 32% on Good News.
New data show a single dose of AbCellera's menopause treatment, ABCL635, reduces how often patients with menopause experience hot flashes.
AbCellera menopause drug cuts hot flashes in mid-stage trial, shares rise
AbCellera said Monday its experimental menopause treatment significantly reduced the frequency and severity of hot flashes in a mid-stage trial, sending its shares up 24% in premarket trading.
AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635.
AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Aug. 10...
AbCellera Biologics Earnings Call Transcript: Q2 2026
Enrollment and dosing for the ABCL635 phase II trial in hot flashes completed ahead of schedule, with top-line data imminent. Two major TCE collaborations added over $110 million in upfront cash and potential for over $4 billion in deal value. Cash and liquidity remain strong, supporting at least three years of pipeline investment.
AbCellera Biologics Slides: Q2 2026
AbCellera Biologics has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 5, 2026.
AbCellera Biologics Earnings release: Q2 2026
AbCellera Biologics released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
AbCellera Biologics Quarterly report: Q2 2026
AbCellera Biologics has published its Q2 2026 quarterly earnings report on August 5, 2026.
AbCellera Reports Q2 2026 Business Results
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Reports Q2 2026 Business Results.
AbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions.
AbCellera to Report Second Quarter 2026 Financial Results on August 5, 2026
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report Second Quarter 2026 Financial Results on August 5, 2026.
AbCellera Appoints Dr. Lynn Seely to its Board of Directors
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Appoints Dr. Lynn Seely to its Board of Directors.
Jazz Pharma, AbCellera ink antibody deal worth up to $876 million
Jazz Pharmaceuticals has signed a research collaboration and licensing agreement with Canada's AbCellera to develop T-cell engaging multispecific antibodies for cancer, the companies said on Wednesd...
Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies
DUBLIN & VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies.
AbCellera Appoints Dr. Victor Sandor to its Board of Directors
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Appoints Dr. Victor Sandor to its Board of Directors.
AbCellera Biologics Transcript: Jefferies Global Healthcare Conference 2026
A strategic shift to a proprietary pipeline is underway, with lead asset ABCL635 showing promising phase I safety and target engagement for menopause-related hot flashes. Phase II results are expected in Q3, aiming for a differentiated, once-monthly therapy in a $6B market.
AbCellera Biologics Transcript: Bank of America Global Healthcare Conference 2026
The company has evolved from a discovery partner to a clinical-stage developer, leveraging its proprietary antibody platform and significant capital to advance a differentiated pipeline. Lead asset ABCL635 targets NK3R with promising safety and efficacy, while additional programs in autoimmunity and oncology are advancing with strategic confidentiality.
AbCellera Biologics Earnings Call Transcript: Q1 2026
Strong Q1 2026 liquidity and pipeline progress, highlighted by ABCL635's phase I data and phase II advancement for non-hormonal VMS treatment. Revenue doubled year-over-year, R&D investment increased, and net loss narrowed. Top-line phase II data expected Q3 2026.
AbCellera Biologics Earnings release: Q1 2026
AbCellera Biologics released its Q1 2026 earnings on May 11, 2026, summarizing the period's financial results.